Literature DB >> 19877930

Product development in tissue engineering.

M J Lysaght1.   

Abstract

Tissue engineering may be defined as the application of the principles and techniques of biomedical engineering to products and processes involving living cells. As such it is located at the confluence of traditional medical device technology, molecular pharmacology, and cell biology. Effective function at this interface has proven both elusive and critical in tissue engineering research and is likely to remain a determinant of success or failure as products move from research through development and into clinical practice. As a further challenge, regulatory processes, traditions, and approval pathways are rather different for medical devices than for Pharmaceuticals and biologies, and commercialization of hybrid products will require knowledge and expertise in both areas. This review compares and contrasts the development cycle for medical devices and pharmaceutical products and highlights the major development issues facing emerging tissue engineering products.

Year:  1995        PMID: 19877930     DOI: 10.1089/ten.1995.1.221

Source DB:  PubMed          Journal:  Tissue Eng        ISSN: 1076-3279


  4 in total

1.  Regenerative medicine: the emergence of an industry.

Authors:  Robert M Nerem
Journal:  J R Soc Interface       Date:  2010-09-15       Impact factor: 4.118

2.  An Overview of the Tissue Engineering Market in the United States from 2011 to 2018.

Authors:  Yu Seon Kim; Mollie M Smoak; Anthony J Melchiorri; Antonios G Mikos
Journal:  Tissue Eng Part A       Date:  2018-09-04       Impact factor: 3.845

Review 3.  Tissue engineering and regenerative medicine: recent innovations and the transition to translation.

Authors:  Matthew B Fisher; Robert L Mauck
Journal:  Tissue Eng Part B Rev       Date:  2013-02       Impact factor: 6.389

4.  Biochemical and Biophysical Cues in Matrix Design for Chronic and Diabetic Wound Treatment.

Authors:  Yun Xiao; Samad Ahadian; Milica Radisic
Journal:  Tissue Eng Part B Rev       Date:  2016-08-19       Impact factor: 6.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.